Eli Lilly (LLY) Director Reports 15.705 Stock-Unit Acquisition via Deferral
Rhea-AI Filing Summary
Ralph Alvarez, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 15.705 common stock units at a reported price of $748.19, and after the transaction the reporting person is shown as beneficially owning 55,137.85 shares (direct) and 758 shares indirectly through a trust. The filing discloses these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock following the reporting person’s separation from service. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
Positive
- Deferral into stock units indicates the director elected equity-based compensation rather than cash, aligning interests with shareholders
- Clear disclosure of transaction date, amount acquired, post-transaction ownership, and indirect ownership via trust
Negative
- Settlement deferred until separation from service, so the units are not currently settled into voting shares
- Reporting person disclaims beneficial ownership except for pecuniary interest, which limits clarity on voting/control influence
Insights
TL;DR: Routine director deferral of compensation into stock units; disclosures align with typical corporate governance practice.
The Form 4 documents a director electing to defer cash compensation into stock units under an established deferral plan, with settlement conditioned on separation from service. This is a customary approach for board compensation, preserving tax deferral and aligning long-term interests with shareholders. The report also clarifies indirect ownership via a trust and contains the standard disclaimer limiting beneficial ownership to pecuniary interest. There is no evidence in the filing of option exercises, share sales, or other atypical transactions that would raise governance concerns.
TL;DR: Filing appears complete and procedural; key settlement timing and ownership forms are disclosed.
The Form 4 includes required elements: transaction date, transaction code (A), number of units acquired, price, post-transaction beneficial ownership totals, and signature authorization. The explanation specifies that the acquisition resulted from a deferral election and that settlement occurs upon separation, which affects when shares convert to deliverable stock. The indirect ownership through a trust and the pecuniary-interest disclaimer are properly noted, reducing ambiguity about control or voting power. No regulatory flags are evident from the disclosed items.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 15.705 | $748.19 | $12K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
